DSG2 Compositions and Methods for the Treatment of COVID-19

JP2024500250A5Pending Publication Date: 2024-11-29ARVADA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023560254
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-02
Filing Date
2021-12-15
Publication Date
2024-11-29

AI Technical Summary

Benefits of technology

がもたらされることを指す。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates primarily to compositions and methods for treating COVID-19 by administering the compositions disclosed herein, including the treatment of post-COVID-19 syndrome and cardiomyopathy using the compositions described in this disclosure.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Sequence Listing This application has been submitted with a Sequence Listing in electronic format. The Sequence Listing file was created on December 10, 2021. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

[0002] Disclosure Fields The present disclosure relates primarily to DSG2-based methods for treating COVID-19 by administering compositions disclosed herein, including the treatment of therapeutic indications such as myocardial inflammation and / or reduced ejection fraction / heart failure / cardiomyopathy associated with long-term effects of COVID-19, including but not limited to post-COVID-19 syndrome and post-COVID-19 cardiac syndrome, as well as the treatment of diseases associated with DSG2 autoantibodies, such as arrhythmogenic right ventricular cardiomyopathy (ARVC), sarcoidosis. [Background technology]

[0003] In early 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic, infecting millions of people with coronavirus disease (referred to as COVID-19) (Non-Patent Document 1). This has resulted in more than one million deaths worldwide. Patients infected with SARS-CoV-2 may experience a range of clinical symptoms, from asymptomatic to severe disease. Recent studies suggest that in some cases, symptoms may continue after initial recovery, even in those who had mild symptoms. This condition has been termed post-COVID-19 syndrome, or "long COVID-19." In addition, patients may develop reduced ejection fraction and cardiomyopathy, even after the acute COVID-19 infection has subsided. Post-COVID-19 cardiac signs and symptoms may coexist with effects on other organ systems, or may be present alone. Patients with post-COVID cardiomyopathy range from asymptomatic patients to those with fulminant heart failure, arrhythmias, and / or sudden cardiac death.

[0004] The COVID-19 virus, SARS-CoV-2, affects multiple organ systems, especially the lungs and heart. Elevations in cardiac biomarkers, especially high-sensitivity troponin and / or creatine kinase MB, are commonly observed in patients with COVID-19 infection. In a review of clinical analyses conducted by Bavishi et al., myocardial injury was found to occur in 20% of patients with COVID-19 infection (Non-Patent Document 2). Possible mechanisms of myocardial injury associated with COVID-19 include, but are not limited to, 1) pathological T-cell and monocyte-mediated hyperinflammation and cytokine storm leading to myocarditis, 2) respiratory failure and hypoxemia leading to cardiomyocyte injury, 3) downregulation of ACE2 expression and subsequent protective signaling pathways in cardiomyocytes, 4) hypercoagulation and development of coronary microvascular thrombosis, 5) diffuse endothelial injury, and / or 6) inflammation and / or stress leading to coronary plaque rupture or supply-demand mismatch resulting in myocardial ischemia / myocardial infarction.

[0005] Post-COVID-19 syndrome has also been associated with multiple organ damage, including cardiovascular damage. Imaging studies performed months after recovery from COVID-19 infection have shown persistent damage to the heart muscle, even in people who experienced only mild COVID-19 symptoms. Post-COVID-19 syndrome also appears to be associated with myocarditis and / or cardiomyopathy with an increased risk of arrhythmias.

[0006] Currently, there is a lack of therapeutic strategies for the treatment and / or management of COVID-19 and post-COVID-19 syndrome. The cardiac manifestations of COVID-19 place a great deal of stress on an already overburdened healthcare system, as these patients require significant resources and potential intensive care support. In particular, there is an urgent need to develop therapeutics that inhibit the inflammatory response to reduce the incidence of myocardial injury and mortality associated with COVID-19 and post-COVID-19 syndrome. The present disclosure provides DSG2 fusion polypeptide-based compositions and methods for treating diseases, such as, but not limited to, COVID-19, post-COVID-19 syndrome, and / or post-COVID-19 cardiac syndrome. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Wu et al.,2020 Nature 579,265-269 [Non-Patent Document 2] Prog Cardiovasc Dis.2020 September-October;63(5):682-689 Summary of the Invention

[0008] The present disclosure provides compositions comprising isolated polypeptides. The polypeptides of the present disclosure may comprise all or a portion of a DSG2 protein. In some embodiments, the isolated polypeptide is a desmoglein 2 (DSG2) fusion polypeptide. The DSG2 fusion polypeptide may comprise (a) all or a portion of a DSG2 protein (SEQ ID NO: 1); and / or (b) all or a portion of an immunoglobulin protein. In one embodiment, the DSG2 polypeptide may comprise a portion of a DSG2 protein. The portion of the DSG2 protein may comprise an extracellular region of the DSG2 protein. In some aspects, the entire extracellular region of DSG2 may be included in the fusion polypeptide. In one embodiment, the entire extracellular region of DSG2 comprises the amino acid sequence of SEQ ID NO: 3. An embodiment of the present disclosure may also comprise a portion of the extracellular region of DSG2. For example, a portion of the extracellular region can be extracellular cadherin domain 1 (EC1), extracellular cadherin domain 2 (EC2), extracellular cadherin domain 3 (EC3), extracellular cadherin domain 4 (EC4), and / or extracellular anchor domain (EA). In some embodiments, the DSG2 fusion polypeptide comprises two domains of the extracellular region. For example, the two domains can be EC4EA, EC1EC2, EC2EC3, EC3EC4, EC1EA, EC1EC3, EC2EC4, and / or EC3EA. In some embodiments, the DSG2 fusion polypeptide comprises three domains of the extracellular region. For example, the three domains can be EC1EC3EA, EC1EC4EA, EC1EC3EA, EC3EC4EA, EC1EC2EC3, EC2EC3EC4, and / or EC2EC4EA. In some embodiments, the DSG2 fusion polypeptide comprises four domains of the extracellular region. For example, the three domains can be EC1EC2EC4EA, EC2EC3EC4EA, EC1EC2EC3EC4EA, EC1EC2EC3EC4, and / or EC1EC2EC3EA.

[0009] The DSG2 fusion polypeptide may comprise a portion of an immunoglobulin. The portion may be an Fc region, a Fab region, a heavy chain variable (VH) domain, a heavy chain constant domain, a light chain variable (VL) domain, and / or a light chain constant domain. In one embodiment, the portion of an immunoglobulin may be an Fc region. The immunoglobulin may be an IgG, an IgM, an IgA, an IgD, and / or an IgE. In a non-limiting example, the immunoglobulin may be an IgG. The composition may comprise an IgG, such as an IgG1, an IgG2, an IgG3, and / or an IgG4. Non-limiting examples of portions of immunoglobulins useful in the present disclosure include an IgG1 Fc region (SEQ ID NO:5), an IgG2 Fc region (SEQ ID NO:7), an IgG3 Fc region (SEQ ID NO:9), an IgG4 Fc region (SEQ ID NO:11), an IgG1 heavy chain constant domain (SEQ ID NO:4), an IgG2 heavy chain constant domain (SEQ ID NO:6), an IgG3 heavy chain constant domain (SEQ ID NO:8), an IgG4 or heavy chain constant domain (SEQ ID NO:10).

[0010] The polypeptide of the present disclosure may further comprise a linker and / or a signal sequence. The linker may be about 5 amino acids to about 50 amino acids in length. In one embodiment, the linker may be GGGGS (SEQ ID NO: 12). In another aspect, the linker may be EAAAK (SEQ ID NO: 13).

[0011] The present disclosure also provides methods of treatment using the compositions described herein. In some embodiments, the present disclosure provides methods of treating post-COVID-19 syndrome. Such methods may include i) contacting a subject with an isolated polypeptide of the present disclosure, and (ii) measuring one or more symptoms associated with post-COVID-19 syndrome selected from the group consisting of arrhythmia, myocarditis, heart failure, shortness of breath, fatigue, edema, orthopnea, limitations to exertion, decreased cognitive ability, palpitations, dizziness, fainting, and / or lightheadedness. Treatment with a polypeptide of the present disclosure may be effective in improving one or more symptoms associated with post-COVID-19 cardiac syndrome. In some embodiments, the post-COVID-19 subject has previously been diagnosed with COVID-19 using methods known in the art. In one aspect, the subject's serum has detectable levels of anti-SARS-CoV-2 antibodies. In some embodiments, the subject's serum does not have detectable levels of anti-SARS-CoV-2 antibodies. Also provided herein is a method of treating a subject with COVID-19 by administering a composition described herein. In some embodiments, serum from a post-COV1D-19 or COVID-19 subject may have anti-DSG2 antibodies.

[0012] The present disclosure also provides a method of treating a condition associated with serum DSG2 autoantibodies. Such a method may include administering to a subject a composition described herein or a cell expressing a composition described herein. In some embodiments, the condition may be a cardiomyopathy. In some aspects, the condition may be an autoimmune disease.

[0013] The present disclosure provides a method of treating cardiomyopathy in a subject. Such a method may include contacting a subject with an isolated polypeptide or cell of the present disclosure, followed by measuring one or more symptoms associated with cardiomyopathy, such as arrhythmia, palpitations, myocarditis, heart failure, low cardiac output, and / or reduced ejection fraction. As a non-limiting example, the cardiomyopathy may be arrhythmogenic right ventricular cardiomyopathy (ARVC). Cardiomyopathy may also be caused by a virus (e.g., SARS-CoV2, adenovirus, hepatitis virus, hepatitis C virus, parvovirus, herpes simplex virus, echovirus, Epstein-Barr virus, rubella, cytomegalovirus, or HIV), a bacterium (Staphylococcus, Streptococcus, or Borrelia), a parasite (Trypanosoma or Toxoplasma), or a fungus (Candida, Aspergillus, or Histoplasma). In some embodiments, the subject may have a detectable level of anti-DSG2 antibodies in serum. [Brief description of the drawings]

[0014] The foregoing and other objects, features and advantages of particular embodiments of the present disclosure will become apparent from the following description and the accompanying drawings, in which: The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the present disclosure. [Figure 1] Figure 1 shows a comparison of the levels of anti-DSG2 antibody signal in healthy controls (N=152), post-COVID-19 (N=300), and arrhythmogenic right ventricular cardiomyopathy samples (N=5). HC, healthy controls, PC, post-COVID-19, ARVC, arrhythmogenic right ventricular cardiomyopathy, S / NC, signal / negative controls. Each individual diamond represents a single serum sample. Box and whisker limits represent the 25-75th and 10-90th percentiles, respectively. P values ​​are based on nonparametric rank-based Wilcoxon-Mann-Whitney two-tailed test. [Figure 2A] Figure 2A is a bar graph showing anti-DSG2 antibody signals at 6 and 9 months in all samples analyzed by month of collection after COVID-19 infection (N=300). [Figure 2B]Figure 2B is a bar graph showing anti-DSG2 antibody signals at 6 and 9 months in paired samples analyzed by month of collection after COVID-19 infection (N=17). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Detailed Description I. Introduction The recent outbreak of COVID-19 causes severe respiratory disease in humans and threatens human health worldwide. The novel virus that causes COVID-19 has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV), because SARS-CoV-2 is closely related to the SARS virus.

[0016] SARS-CoV-2 particles use a special surface glycoprotein (spike protein) to enter host cells by binding to angiotensin-converting enzyme 2 (ACE2), which is most abundant on type II alveolar epithelial cells in the lungs. The coronavirus genome then replicates inside the host cell. The density of ACE2 receptors in each tissue correlates with the severity of COVID-19 infection in that tissue. ACE2 receptors are also expressed on the outer surface of cells in the arteries, heart, kidneys, and intestines. As a result, COVID-19 can cause multiple organ failure in very severe cases.

[0017] Symptoms of COVID-19 range from mild (e.g., fever, cough, shortness of breath) to severe, including pneumonia and acute respiratory distress syndrome (ARDS), sepsis and septic shock, multiple organ failure including acute kidney injury, and cardiac damage. Although respiratory disease is the main clinical manifestation of COVID-19 infection, multiple organ failure can also occur. A multicenter study analyzing COVID-19 fatal cases observed that myocardial damage was the cause of death in 40% of cases (Ruan Q.et al.Intensive Care Med.2020;46(5):846-848). Various cardiac complications, including arrhythmias, myocarditis, and acute myocardial injury, are associated with active COVID-19 infection. Systemic inflammation, direct damage to cardiomyocytes, cytokine storm, and hypoxia are some of the proposed mechanisms in the multifactorial pathophysiology. Arrhythmias associated with COVID-19 can also be attributed to treatment with azithromycin, hydroxychloroquine, and some antiviral drugs, which can cause QT prolongation. Acute myocardial injury in COVID-19 ranges from asymptomatic elevation of cardiac troponin to fulminant myocarditis and circulatory shock. Myocardial injury may manifest alone or occur together with arrhythmias based on the clinical course of the infection.

[0018] The proinflammatory environment and increased sympathetic stimulation in COVID-19 may further increase the risk of cardiovascular complications such as arrhythmias, worsening of pre-existing heart failure (HF), or the development of new HF. In patients with severe disease, hypoxia and electrolyte disturbances may further increase the risk of arrhythmias.

[0019] In some cases, patients may experience symptoms weeks, months, or years after viral particles have been detected in patient samples (referred to herein as post-COVID-19 syndrome or "long COVID-19" or post-viral syndrome). Post-COVID-19 syndrome may also be associated with cardiac symptoms, referred to herein as post-COVID-19 cardiac syndrome. Many patients who have recovered from COVID-19 show persistent inflammation in the myocardium as measured by MRI. In one study, up to 60% of symptomatic and asymptomatic COVID-19 patients showed MRI evidence of ongoing myocardial inflammation an average of 71 days after recovery from the acute phase of COVID-19 (Puntmann et al. JAMA Cardiol. 2020;5(11):1265-1273; the entire contents of which are incorporated herein by reference). In a smaller study, 15% of athletes showed signs of myocarditis after recovery from COVID-19 (Metzel et al. 2020, HSS Journal, Vol. 16, pp. 102-107). A significant proportion of patients with post-COVID-19 syndrome subsequently develop reduced cardiac function, particularly reduced ejection fraction, with or without overt symptoms of heart failure. For clarity, patients with post-COVID-19 cardiac symptoms may be referred to herein as post-COVID-19 cardiac syndrome. Patients with post-COVID-19 syndrome also experience chronic fatigue syndrome, which may be caused by undiagnosed reduced cardiac output. Symptoms may include shortness of breath, fatigue, edema, orthopnea, limited movement and reduced cognitive ability due to low cardiac output ("brain fog"), arrhythmia, palpitations, dizziness, fainting, lightheadedness, heart failure, hospitalization due to heart failure and / or arrhythmia, and the like. In some cases, death may occur as a result of heart failure and / or arrhythmia. In some embodiments, post-COVID-19 syndrome may not be associated with cardiac symptoms.

[0020] Cardiac symptoms, including arrhythmias, are associated with other diseases, such as, but not limited to, arrhythmogenic right ventricular cardiomyopathy (ARVC). Similar to ARVC, patients with COVID-19 and / or post-COVID-19 syndrome also show worsening cardiac function during physical activity. In the case of ARVC, Chatterjee et al. identified autoantibodies against cardiac desmoglein 2 (DSG2) protein as a common feature in the sera of ARVC patients (Chatterjee D et al., Eur Heart J. 2018;39(44):3932-3944; the entire contents of which are incorporated herein by reference). These autoantibodies were specific for ARVC, as they were essentially absent from two independent sets of control sera, as well as from sera of patients with other forms of inherited cardiomyopathies. DSG2 antibodies can also be found in some cases of sarcoidosis, a systemic inflammatory disease that causes granulomas in organs, including, but not limited to, the heart. Anti-DSG2 antibodies are also found in sarcoid patients with cardiac involvement (Suna et al. 2020, Eur. Heart Journal, Vol. 41, Suppl. 2, Nov. 2020, ehaa946.2127; the entire contents of which are incorporated herein by reference). Patients diagnosed with dilated cardiomyopathy may have mutations in the same desmosomal proteins associated with ARVC. These findings suggest that some dilated cardiomyopathy patients may in fact have ARVC-like disease mediated by DSG2 antibodies, but may be diagnosed with dilated cardiomyopathy because they do not fit the typical age or symptoms associated with ARVC. Anti-DSG2 autoantibodies are thought to arise in the context of infections, which are known to typically affect the myocardium directly, when cardiomyocyte damage is combined with immune system activation. From a pathogenesis perspective, viral infections such as COVID-19 typically trigger a vigorous immune response that is important for viral clearance, resulting in a cascade of events involving both the innate and adaptive immune systems. Direct and indirect myocardial injury can also be caused by COVID-19 infection, which exposes myocardial proteins to an activated immune system. Immunological changes have also been observed in patients with COVID-19 infection.These range from maladaptive immune responses and aberrant cytokine / chemokine production to hyperactivation of T cells and increased numbers of activated monocytes, macrophages and neutrophils (Chang, SE, et al. Nature Communications 2021;12:5417; Liu, Y., et al. Curr. Opin. Rheumatol. 2021;33:155-162; Lee, CCE, et al. Diseases 2021;9:47; the contents of each of which are incorporated by reference in their entirety into this specification).

[0021] COVID-19 has infected at least 200 million people worldwide to date, with approximately 4.5 million deaths attributable to COVID-19 infection. There is increasing awareness that COVID-19 infection can cause a variety of long-term sequelae, of which cardiac involvement appears to be the least recognized, as its symptoms may originate in other organ systems.

[0022] COVID-19 infection has been associated with MRI evidence of myocardial involvement and favorably resolving arrhythmias, independent of pre-existing conditions, the severity and overall course of acute illness, and time from initial diagnosis.Frank cardiomyopathy has been reported in post-COVID-19 patients, although the proportion of patients who subsequently develop reduced ejection fraction is currently poorly understood.

[0023] Findings of cardiomyopathy and susceptibility to arrhythmias are also observed in arrhythmogenic right ventricular cardiomyopathy (ARVC). Antibodies against the desmosomal protein desmoglein 2 (DSG2) have been shown to be present in ARVC patients (Diptendu Chatterjee D.,et al.EHJ 2018(39)3932-3944; the contents of which are incorporated herein by reference in their entirety). Concentrations of anti-DSG2 antibodies positively correlate with arrhythmia burden, and the presence of these antibodies in borderline ARVC cases predicts the development of fulminant ARVC. Exposure of iPSC-derived cardiomyocytes to anti-DSG2 antibodies reduces gap junction function, which may reflect direct cardiotoxicity. Taken together, these data suggest that anti-DSG2 antibodies may play a role in cardiac pathology. The present disclosure also provides evidence showing that anti-DSG2 antibody levels are elevated in COVID-19 patients even 6-9 months after diagnosis.

[0024] It has been hypothesized that viral infections, including COVID-19, contribute to autoimmune responses, for example, by exposing previously hidden cryptic epitopes on damaged cells to the activated immune system (Ehrenfeld M., et al. Autoimmunity Reviews 2020 102597; the contents of which are incorporated herein by reference in their entirety). The high incidence of cardiac lesions seen in COVID-19 infections indicates that anti-DSG2 autoantibodies may be generated as a result.

[0025] The presence of arrhythmias, together with the role of the immune system in the progression of COVID-19, post-COVID-19 syndrome and ARVC, suggests the involvement of DSG2 autoantibodies in the pathogenesis of these diseases. Thus, strategies targeting anti-DSG2 antibodies (e.g., DSG2 autoantibodies) may be beneficial for the treatment of COVID-19, post-COVID-19 syndrome and / or ARVC.

[0026] The present disclosure provides compositions and methods related to DSG2 fusion polypeptides for targeting anti-DSG2 antibodies. Thus, the DSG2 fusion polypeptides of the present disclosure may be a viable therapeutic strategy in the treatment of COVID-19, post-COVID-19 cardiac syndrome, and / or ARVC. DSG2 fusion polypeptides may also be used to treat other diseases associated with cardiac cell damage, such as, but not limited to, arrhythmogenic cardiomyopathy (AC), sarcoidosis, dilated cardiomyopathy due to anti-DSG2 autoantibodies, and viral infections, including but not limited to those caused by coxsackievirus, adenovirus, echovirus, parvovirus, rubella, and / or cytomegalovirus.

[0027] II. Composition In some embodiments, the present disclosure provides compositions comprising DSG2 fusion polypeptides. The compositions described herein can bind to or interact with anti-DSG2 antibodies. In one embodiment, the compositions of the present disclosure can modulate the activity of anti-DSG2 antibodies. In one embodiment, the compositions of the present disclosure can inhibit the activity of anti-DSG2 antibodies.

[0028] In some embodiments, the present disclosure includes DSG2 protein. In some aspects, the DSG2 protein can be the whole DSG2 protein or a part of the DSG2 protein. In some embodiments, the DSG2 protein can be fused to any other protein or protein fragment.

[0029] The DSG2 fusion polypeptide of the present disclosure may include all or a portion of a DSG2 protein and all or a portion of an immunoglobulin protein. In some embodiments, the DSG2 fusion polypeptide may further include a linker and / or a signal peptide. In some embodiments, all or a portion of a DSG2 protein may be fused to a protein that is not an immunoglobulin. The DSG2 protein may be fused to a protein or a fragment of a protein that can improve the expression of the DSG2 protein in vitro or in vivo.

[0030] DSG2 mutations in the intercalated discs of cardiac cells are believed to be involved in cardiac diseases including arrhythmias, dilated cardiomyopathy, and especially ARVC (arrhythmogenic right ventricular cardiomyopathy). Chatterjee et al. identified autoantibodies against cardiac DSG2 protein as a common feature in the serum of ARVC patients (Chatterjee D et al., Eur Heart J. 2018; 39(44): 3932-3944; the entire contents of which are incorporated herein by reference). These autoantibodies were specific to ARVC as they were essentially absent from two independent sets of control sera as well as from sera from patients with other forms of inherited cardiomyopathy. The presence of DSG2 autoantibodies identified by Chatterjee et al. suggests that targeting DSG2 antibodies may be a therapeutic strategy in the treatment of cardiomyopathies associated with diseases such as, but not limited to, ARVC and / or COVID-19. The present disclosure provides DSG2 fusion polypeptides as a therapeutic strategy for targeting DSG2 autoantibodies. In some embodiments, the DSG2 fusion polypeptides of the present disclosure may bind to DSG2 autoantibodies. In some embodiments, binding of a DSG2 fusion polypeptide of the present disclosure to a DSG2 autoantibody disables binding of the autoantibody to endogenous DSG2 in the subject. In this aspect of the present disclosure, the DSG2 fusion polypeptide functions as a decoy protein or ligand trap.

[0031] Chatterjee et al. propose that DSG2 protein may contain epitopes that may be exposed or released into the intercellular space and / or circulatory system as a result of DSG2 mutations. Exposure of these epitopes may also occur due to cardiac injury (such as, but not limited to, infectious myocarditis and / or cardiac trauma). In some embodiments, the compositions of the present disclosure may not contain any mutations. Such released DSG2 protein may bind to antigen-presenting cells to stimulate T cell responses and generate the observed autoantibodies. Exposure of cryptic epitopes due to genetic mutations may contribute to other forms of autoimmunity. In some embodiments, the DSG2 fusion polypeptides of the present disclosure may contain epitopes that include one or more mutations in DSG2.

[0032] The DSG2 fusion polypeptide may be a soluble and / or recombinant polypeptide. The arrangement of components in the DSG2 fusion polypeptide may be optimized to achieve proper protein expression and / or the intended therapeutic effect. In some embodiments, the DSG2 fusion polypeptide may include a format described herein. The formats provided herein include components from N-terminus to C-terminus separated by a ";" between the components. Non-limiting examples of formats for DSG2 fusion polypeptides include: (i) all or a portion of a DSG2 protein; Fc region; (ii) Fc region; all or a portion of a DSG2 protein; (iii) signal sequence; all or a portion of a DSG2 protein; Fc region; (iv) signal sequence; Fc region; all or a portion of a DSG2 protein; (v) all or a portion of a DSG2 protein; linker; Fc region; (vi) Fc region; linker; all or a portion of a DSG2 protein; (vii) signal sequence; all or a portion of a DSG2 protein; linker; Fc region; (viii) signal sequence; Fc region; linker; all or a portion of a DSG2 protein.

[0033] DSG2 protein In some embodiments, the DSG2 fusion polypeptide of the present disclosure may comprise the entire DSG2 protein. Desmosomal cadherin desmoglein 2 (DSG2) is a transmembrane cell adhesion protein that is widely expressed in epithelial and non-epithelial tissues, such as the heart, intestine, and epidermis. DSG2 has been shown to regulate many cellular processes, including proliferation and apoptosis. In epithelial and muscle cells, DSG2 is a component of cell-cell adhesion structures, and its cytoplasmic tail interacts with a series of proteins that directly contact cell adhesion regulators and cell-cell junction / cell type regulators. In some embodiments, the DSG2 protein is the human DSG2 protein (UniProt ID: Q14126; ENSEMBL protein ID: ENSP00000261590.8), which consists of 1,118 amino acids and comprises the amino acid sequence of SEQ ID NO:1. In one embodiment, the DSG2 protein may be encoded by the nucleic acid sequence of SEQ ID NO: 2 (NCBI Reference Sequence: NM_001943.5; ENSMBL ID: ENST00000261590.13).

[0034] In some embodiments, a DSG2 fusion polypeptide of the disclosure can be a fully processed DSG2 protein comprising amino acids 50-1118 of SEQ ID NO:1. The DSG2 protein may also comprise one or more mutations relative to the sequence of SEQ ID NO:1. In some embodiments, the DSG2 protein mutation may be a mutation associated with a disease state. In one embodiment, the disease state may be arrhythmogenic right ventricular dysplasia / cardiomyopathy. In some embodiments, a DSG2 fusion polypeptide of the present disclosure may comprise an epitope comprising one or more mutations in DSG2. As a non-limiting example, a DSG2 fusion polypeptide may comprise one or more mutations in the region of amino acids 485-531 and / or amino acids 586-610 of SEQ ID NO:1.

[0035] DSG2 belongs to the cadherin superfamily of cell adhesion proteins and shares three distinct regions in common: an extracellular region, a transmembrane domain, and an intracellular signaling region. In some embodiments, the extracellular region of DSG2 can include the amino acid sequence of SEQ ID NO: 3, which is amino acids 50-609 of SEQ ID NO: 1. The extracellular region of the cadherin family of proteins contains variable numbers of repeats of calcium-binding motifs, known as cadherin motifs or EC domains. DSG2 includes four EC domains, referred to herein as EC1, EC2, EC3, and EC4. DSG2 also includes an extracellular anchor (EA) domain that is membrane proximal. In some embodiments, a DSG2 fusion polypeptide of the present disclosure can include the entire extracellular region of DSG2. In some aspects, a DSG2 fusion polypeptide can include at least one domain, such as, but not limited to, EC1, EC2, EC3, EC4, and / or EA. In some embodiments, the EC1 domain can be amino acids 50-155 of SEQ ID NO: 1. In some embodiments, the EC2 domain can be amino acids 151-268 of SEQ ID NO:1. In some embodiments, the EC3 domain can be amino acids 264-384 of SEQ ID NO:1. In some embodiments, the EC4 domain can be amino acids 382-495 of SEQ ID NO:1. In some embodiments, the EA domain can be amino acids 491-608 of SEQ ID NO:1. Table 1 shows the amino acid sequence of the DSG2 protein and the amino acid sequence of the extracellular region of DSG2. In some embodiments, the DSG2 protein of the disclosure can have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to any of the sequences in Table 1 or fragments of the sequences in Table 1.

[0036] [Table 1]

[0037] The DSG2 fusion polypeptide of the present disclosure may comprise one or more domains of the extracellular region of DSG2. The domain of the extracellular region of DSG2 may comprise one or more repeats of the EC domain or the EA domain in tandem or in mixed order. For example, the DSG2 fusion polypeptide may comprise two, three or more repeats of the EC1, EC2, EC3, EC4 or EA domain. When multiple domains and / or multiple repeats of a domain of the extracellular region of DSG2 are present, the domains may be operably linked via a linker as described herein.

[0038] In some embodiments, a DSG2 fusion polypeptide may comprise two domains of the extracellular region of DSG2. Non-limiting examples of domains of the extracellular region of DSG2 present in a fusion polypeptide of the present disclosure include EC1EC2, EC1EC3, EC1EC4, EC1EA, EC2EC1, EC2EC3, EC2EC4, EC2EA, EC3EC1, EC3EC2, EC3EC4, EC3EA, EC4EC1, EC4EC2, EC4EC3, EC4EA, EAEC1, EAEC2, EAEC3, and / or EAEC4.

[0039] In some embodiments, a DSG2 fusion polypeptide may comprise three domains of the extracellular region of DSG2. Non-limiting examples of domains of the extracellular region of DSG2 present in a fusion polypeptide of the present disclosure include EC1EC2EC3, EC1EC2EC4, EC1EC2EA, EC1EC3EC2, EC1EC3EC4, EC1EC3EA, EC1EC4EC2, EC1EC4EC3, EC1EC4EA, EC1EAEC2, EC1EAEC3, EC1EAEC4, EC2EC1EC3, EC2EC1EC4, EC2EC1EA, EC2EC3EC1, EC2EC3EC4, EC2EC3EA, EC2EC4EC1, EC2EC4EC3, EC2EC4EA, EC2EAEC1, EC2EAEC3, EC2EAEC4, EC3EC1EC2, EC3EC1EC4, EC3EC1EA, EC3EC2EC1 , EC3EC2EC4, EC3EC2EA, EC3EC4EC1, EC3EC4EC2, EC3EC4EA, EC3EAEC1, EC3EAEC2, EC3EAEC4, EC4EC1EC2, EC4EC1EC3, EC4EC1EA, EC4EC2EC1, EC4EC2EC3, EC4EC2EA, EC4EC3EC1, EC4EC3EC2, EC4EC3EA, EC4EAEC1, EC4EAEC2, EC4EAEC3, EAEC1EC2, EAEC1EC3, EAEC1EC4, EAEC2EC1, EAEC2EC3, EAEC2EC4, EAEC3EC1, EAEC3EC2, EAEC3EC4, EAEC4EC1, EAEC4EC2, and / or EAEC4EC3.

[0040] In some embodiments, a DSG2 fusion polypeptide may comprise four domains of the extracellular region of DSG2. Non-limiting examples of domains of the extracellular region of DSG2 present in a fusion polypeptide of the present disclosure include EC1EC2EC3EC4, EC1EC2EC3EA, EC1EC2EC4EC3, EC1EC2EC4EA, EC1EC2EAEC3, EC1EC2EAEC4, EC1EC3EC2EC4, EC1EC3EC2EA, EC1EC3EC4EC2, EC1EC3EC4EA, EC1EC3EAEC2, EC1EC3EAEC4, EC1EC4EC2EC3, EC1EC4EC2EA, EC1EC4EC3EC2, EC1EC4EC3 EA, EC1EC4EAEC2, EC1EC4EAEC3, EC1EAEC2EC3, EC1EAEC2EC4, EC1EAEC3EC2, EC1EAEC3EC4, EC1EAEC4EC2, EC1EAEC4EC3, EC2EC1EC3EC4, EC2EC1 EC3EA, EC2EC1EC4EC3, EC2EC1EC4EA, EC2EC1EAEC3, EC2EC1EAEC4, EC2EC3EC1EC4, EC2EC3EC1EA, EC2EC3EC4EC1, EC2EC3EC4EA, EC2EC3EAEC1, EC 2EC3EAEC4, EC2EC4EC1EC3, EC2EC4EC1EA, EC2EC4EC3EC1, EC2EC4EC3EA, EC2EC4EAEC1, EC2EC4EAEC3, EC2EAEC1EC3, EC2EAEC1EC4, EC2EAEC3EC 1, EC2EAEC3EC4, EC2EAEC4EC1, EC2EAEC4EC3, EC3EC1EC2EC4, EC3EC1EC2EA, EC3EC1EC4EC2, EC3EC1EC4EA, EC3EC1EAEC2, EC3EC1EAEC4, EC3EC2E C1EC4, EC3EC2EC1EA, EC3EC2EC4EC1, EC3EC2EC4EA, EC3EC2EAEC1, EC3EC2EAEC4, EC3EC4EC1EC2, EC3EC4EC1EA, EC3EC4EC2EC1, EC3EC4EC2EA, EC 3EC4EAEC1, EC3EC4EAEC2, EC3EAEC1EC2, EC3EAEC1EC4, EC3EAEC2EC1, EC3EAEC2EC4, EC3EAEC4EC1, EC3EAEC4EC2, EC4EC1EC2EC3, EC4EC1EC2EA,EC4EC1EC3EC2, EC4EC1EC3EA, EC4EC1EAEC2, EC4EC1EAEC3, EC4EC2EC1EC3, EC4EC2EC1EA, EC4EC2EC3EC1, EC4EC2EC3EA, EC4EC2EAEC1, EC4EC2EAEC3, EC4EC3EC1EC2, EC4EC3 EC1EA, EC4EC3EC2EC1, EC4EC3EC2EA, EC4EC3EAEC1, EC4EC3EAEC2, EC4EAEC1EC2, EC4EAEC1EC3, EC4EAEC2EC1, EC4EAEC2EC3, EC4EAEC3EC1, EC4EAEC3EC2, EAEC1EC2EC3, EAE C1EC2EC4, EAEC1EC3EC2, EAEC1EC3EC4, EAEC1EC4EC2, EAEC1EC4EC3, EAEC2EC1EC3, EAEC2EC1EC4, EAEC2EC3EC1, EAEC2EC3EC4, EAEC2EC4EC1, EAEC2EC4EC3, EAEC3EC1EC2, EAEC3EC1EC4, EAEC3EC2EC1, EAEC3EC2EC4, EAEC3EC4EC1, EAEC3EC4EC2, EAEC4EC1EC2, EAEC4EC1EC3, EAEC4EC2EC1, EAEC4EC2EC3, EAEC4EC3EC1, and / or EAEC4EC3EC2.

[0041] In some embodiments, a DSG2 fusion polypeptide may comprise five domains of the extracellular region of DSG2. Non-limiting examples of domains of the extracellular region of DSG2 present in a fusion polypeptide of the present disclosure include EC1EC2EC3EC4EA, EC1EC2EC3EAEC4, EC1EC2EC4EC3EA, EC1EC2EC4EAEC3, EC1EC2EAEC3EC4, EC1EC2EAEC4EC3, EC1EC3EC2EC4EA, EC1EC3EC2EAEC4, EC1EC3EC4EC2EA, EC1EC3EC4EAEC2, EC1EC3EAEC2EC4, EC1EC3EAEC4EC2, EC1EC4EC2EC3E A, EC1EC4EC2EAEC3, EC1EC4EC3EC2EA, EC1EC4EC3EAEC2, EC1EC4EAEC2EC3, EC1EC4EAEC3EC2, EC1EAEC2EC3EC4, EC1EAEC2EC4EC3, EC1EAEC3EC2 EC4, EC1EAEC3EC4EC2, EC1EAEC4EC2EC3, EC1EAEC4EC3EC2, EC2EC1EC3EC4EA, EC2EC1EC3EAEC4, EC2EC1EC4EC3EA, EC2EC1EC4EAEC3, EC2EC1EAE C3EC4, EC2EC1EAEC4EC3, EC2EC3EC1EC4EA, EC2EC3EC1EAEC4, EC2EC3EC4EC1EA, EC2EC3EC4EAEC1, EC2EC3EAEC1EC4, EC2EC3EAEC4EC1, EC2EC4 EC1EC3EA, EC2EC4EC1EAEC3, EC2EC4EC3EC1EA, EC2EC4EC3EAEC1, EC2EC4EAEC1EC3, EC2EC4EAEC3EC1, EC2EAEC1EC3EC4, EC2EAEC1EC4EC3, EC2E AEC3EC1EC4, EC2EAEC3EC4EC1, EC2EAEC4EC1EC3, EC2EAEC4EC3EC1, EC3EC1EC2EC4EA, EC3EC1EC2EAEC4, EC3EC1EC4EC2EA, EC3EC1EC4EAEC2, EC 3EC1EAEC2EC4, EC3EC1EAEC4EC2, EC3EC2EC1EC4EA, EC3EC2EC1EAEC4, EC3EC2EC4EC1EA, EC3EC2EC4EAEC1, EC3EC2EAEC1EC4, EC3EC2EAEC4EC1,EC3EC4EC1EC2EA, EC3EC4EC1EAEC2, EC3EC4EC2EC1EA, EC3EC4EC2EAEC1, EC3EC4EAEC1EC2, EC3EC4EAEC2EC1, EC3EAEC1EC2EC4, EC3EAEC1EC4EC2, EC3EAEC2EC1EC4, EC3EAEC2EC4EC1, EC3EAEC4EC1EC2, EC3EAEC4EC2EC1, EC4EC1EC2EC3EA, EC4EC1EC2EAEC3, EC4EC1EC3EC2EA, EC4EC1EC3EAEC2, EC4EC1EAEC2EC3, EC4EC1EAEC3EC2, EC4EC2EC1EC3EA, EC4EC2EC1EAEC3, EC4EC2EC3EC1EA, EC4EC2EC3EAEC1, EC4EC2EAEC1EC3, EC4EC2EAEC3EC1, EC4EC3EC1EC2EA, EC4EC3EC1EAEC2, EC4EC3EC2EC1EA, EC4EC3EC2EAEC1, EC4EC3EAEC1EC2, EC4EC3EAEC2EC1, EC4EAEC1EC2EC3, EC4EAEC1EC3EC2, EC4EAEC2EC1EC3, EC4EAEC2EC3EC1, EC4EAEC3EC1EC2, EC4EAEC3EC2EC1, EAEC1EC2EC3EC4, EAEC1EC2EC4EC3, EAEC1EC3EC2EC4, EAEC1EC3EC4EC2, EAEC1EC4EC2EC3, EAEC1EC4EC3EC2, EAEC2EC1EC3EC4, EAEC2EC1EC4EC3, EAEC2EC3EC1EC4, EAEC2EC3EC4EC1, EAEC2EC4EC1EC3, EAEC2EC4EC3EC1, EAEC3EC1EC2EC4, EAEC3EC1EC4EC2, EAEC3EC2EC1EC4, EAEC3EC2EC4EC1, EAEC3EC4EC1EC2, EAEC3EC4EC2EC1, EAEC4EC1EC2EC3, EAEC4EC1EC3EC2, EAEC4EC2EC1EC3, EAEC4EC2EC3EC1, EAEC4EC3EC1EC2, and / or EAEC4EC3EC2EC1 are included.

[0042] Non-limiting examples of some of the DSG2 proteins and possible configurations present in DSG2 fusion polypeptides are shown in Table 2. Any of the DSG2 domains listed in Table 2 can be operably linked to another domain or to another DSG2 domain in a fusion polypeptide using any of the linkers provided herein or known in the art. The compositions of the disclosure can include a portion or fragment of any of the domains listed in Table 2. The domain or combination of domains of SEQ ID NO: 1 or SEQ ID NO: 3 included in the polypeptide of the disclosure can be extended by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, or 50 amino acids upstream or downstream of the domains defined in Table 2. In some embodiments, a domain or combination of domains of SEQ ID NO:1 or SEQ ID NO:3 included in a polypeptide of the present disclosure may be truncated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, or 50 amino acids at the N-terminus or C-terminus of the domains defined in Table 2. As a non-limiting example, the extracellular region of the DSG2 protein may extend from amino acids 50-610 of SEQ ID NO:1.

[0043] [Table 2]

[0044] Immunoglobulin Proteins In some embodiments, the DSG2 fusion polypeptides of the present disclosure may comprise all or a portion of an immunoglobulin protein. The immunoglobulin protein may be IgG, IgM, IgA, IgD, and IgE. In one embodiment, the immunoglobulin protein may be IgG. Non-limiting examples of IgG may be IgG1, IgG2, IgG3, and / or IgG4. The DSG2 fusion polypeptides may comprise a region or portion of an immunoglobulin. Non-limiting examples of immunoglobulin regions include Fc regions, Fab regions, heavy chain variable (VH) domains, heavy chain constant domains, light chain variable (VL) domains, and / or light chain constant domains.

[0045] The DSG2 fusion polypeptide may include one or more Fc regions of an immunoglobulin. In some embodiments, the Fc region may include the first constant region immunoglobulin domain (e.g., CH1) or a portion thereof, and optionally a portion of the hinge. In other aspects, the Fc region excludes the first constant region immunoglobulin domain. Thus, Fc may refer to the last two constant region immunoglobulin domains (e.g., CH2 and CH3) of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the N-terminal flexible hinge to these domains. For IgA and IgM, Fc may include the J chain. For IgG, the Fc domain includes immunoglobulin domains Cγ2 and Cγ3 (Cγ2 and Cγ3), and the lower hinge region between Cγ1 (Cγ1) and Cγ2 (Cγ2). In some embodiments, Fc refers to the truncated CH1 domain of an immunoglobulin, as well as CH2 and CH3. Although the boundaries of the Fc region can vary, the human IgG heavy chain Fc region is usually defined to include residues E216, C226 or P230 at its carboxyl terminus, where numbering is according to the EU index as in the Kabat antibody numbering sequence.

[0046] In some embodiments, the immunoglobulin protein may include an additional cell targeting module (sometimes referred to herein as a cell targeting antibody, CTAB). Non-limiting examples of sequences of portions of immunoglobulins are shown in Table 3. In some embodiments, a DSG2 fusion polypeptide may comprise an immunoglobulin protein or portion thereof having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identity to any of the sequences in Table 3 or fragments of the sequences in Table 3.

[0047] [Table 3]

[0048] Signal sequence Signal sequences (sometimes called signal peptides, targeting signals, targeting peptides, localization sequences, transit peptides, leader sequences, or leader peptides) direct proteins (e.g., the polypeptides of the present disclosure) to their designated cellular and / or extracellular locations. Signal sequences can be short (about 5-50 amino acids long) peptides present at the N-terminus of most newly synthesized proteins that direct them to a specific location. Signal sequences are recognized by the signal recognition particle (SRP) and cleaved using type I and type II signal peptide peptidases. Signal sequences from human proteins can be incorporated as DSG2 fusion polypeptides of the present disclosure to direct the polypeptides of the present disclosure to specific cellular and / or extracellular locations. These signal sequences have been experimentally verified and can be cleaved (Zhang et al., Protein Sci. 2004, 13:2819-2824).

[0049] In some embodiments, a signal sequence can be located at the N-terminus or C-terminus of a polypeptide of the disclosure and is, but is not necessarily, cleaved from the polypeptide to yield a "mature" polypeptide, as described herein.

[0050] In some examples, the signal sequence can be a secretory signal sequence derived from a naturally secreted protein, and variants thereof. In some cases, a signal sequence may be used to direct the polypeptide of the present disclosure to the surface membrane of the target cell. Expression of the polypeptide of the present disclosure on the surface of the target cell is useful for limiting the diffusion of the polypeptide of the present disclosure to non-targeted in vivo environments, thereby potentially improving the safety profile of the polypeptide of the present disclosure. Furthermore, membrane presentation of the polypeptide of the present disclosure may allow physiological and qualitative signaling, and may also allow stabilization and recycling of the polypeptide, resulting in a longer half-life.

[0051] The signal sequence may also be a heterologous signal sequence from other organisms, such as viruses, yeast and bacteria, capable of directing a polypeptide of the present disclosure to a specific cellular location, such as the nucleus (eg, EP1209450). Other examples include the aspartic protease (NSP24) signal sequence from Trichoderma (e.g., U.S. Pat. No. 8,093,016 to Cervin and Kim), bacterial lipoprotein signal sequences (e.g., PCT Publication No. 1991 / 09952 to Lau and Rioux), the E. coli enterotoxin II signal peptide (e.g., U.S. Pat. No. 6,605,697 to Kwon et al.), the E. coli secretion signal sequence (e.g., U.S. Patent Application Publication No. 2016 / 090404 to Malley et al.), the lipase signal sequence from methylotrophic yeast (e.g., U.S. Pat. No. 8,975,041), and the signal peptide of DNase from Coryneform bacteria (e.g., U.S. Pat. No. 4,965,197), which can increase secretion of fusion proteins such as enzymes. The contents of each are incorporated herein by reference in their entirety.

[0052] Linker In some embodiments, the DSG2 fusion polypeptide of the present disclosure may include at least one linker. The linker may be located between one or more regions of the polypeptide of the present disclosure. In one embodiment, the linker may be located between all or a portion of the DSG2 protein and all or a portion of the immunoglobulin protein. In one aspect, the linker may be located between one or more domains of the DSG2 protein.

[0053] In some embodiments, the linker can be a polypeptide. In some embodiments, the linker can include a combination of amino acid residues. In some embodiments, the linker can include about 1-50 amino acid residues. In some embodiments, the linker can include about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acid residues.

[0054] The linker of the present disclosure may be about 1-100 amino acids in length and connects any domain / region of the effector module (also called a peptide linker). The linker may be 1-40 amino acids in length, or 2-30 amino acids in length, or 20-80 amino acids in length, or 50-100 amino acids in length. The length of the linker may also be optimized depending on the type of polypeptide configuration and based on the crystal structure of the polypeptide. In some cases, a shorter linker length may be preferably selected. In some embodiments, the peptide linker may be composed of amino acids linked together by peptide bonds, preferably 1 to 20 amino acids linked by peptide bonds, where the amino acids are selected from the 20 naturally occurring amino acids: glycine (G), alanine (A), valine (V), leucine (L), isoleucine (I), serine (S), cysteine ​​(C), threonine (T), methionine (M), proline (P), phenylalanine (F), tyrosine (Y), tryptophan (W), histidine (H), lysine (K), arginine (R), aspartic acid (D), glutamic acid (E), asparagine (N), and glutamine (Q). One or more of these amino acids may be glycosylated, as understood by those of skill in the art. In some embodiments, the amino acids of the peptide linker may be selected from alanine (A), glycine (G), proline (P), asparagine (R), serine (S), glutamine (Q), lysine (K).

[0055] In some embodiments, the linker can be a flexible linker or a rigid linker. Flexible linkers can be composed of small non-polar amino acids (e.g., Gly) or small polar amino acids (e.g., Ser or Thr). These amino acids provide flexibility due to their small size, allowing mobility of the functional domains they link. The most widely used flexible linkers have a sequence consisting mainly of a stretch of Gly and Ser residues ("GS" linker). One example of the most widely used flexible linker has the sequence (Gly-Gly-Gly-Gly-Ser)n. By adjusting the copy number "n", the length of this GS linker can be optimized to achieve proper separation of the functional domains or maintain the required inter-domain interactions. In some embodiments, the linker can contain additional amino acids such as Thr or Ala to maintain flexibility, as well as polar amino acids such as Lys or Glu to improve solubility. In some embodiments, the DSG2 fusion polypeptide can include a flexible linker such as (Gly)8 (SEQ ID NO: 14) consisting purely of glycine residues. The linker sequence avoided large hydrophobic residues in order to maintain good solubility in aqueous solution.

[0056] In some embodiments, the linker may be a rigid linker. A non-limiting example of a rigid linker is a linker having a sequence of (EAAAAK)n (n=2-5) (SEQ ID NO: 15). In some embodiments, the rigid linker may have a proline-rich sequence (XP)n, where X represents any amino acid, preferably Ala, Lys, or Glu.

[0057] In some embodiments, the linker can be GGGGS (SEQ ID NO: 12). In some embodiments, the linker can be GGGGGS (SEQ ID NO: 16) and EAAAK (SEQ ID NO: 13).

[0058] Polynucleotides In some embodiments, the polypeptides of the present disclosure are encoded by a polynucleotide or variants thereof described herein. Exemplary nucleic acids or polynucleotides include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA, including LNA with a β-D-ribo configuration, α-LNA (a diastereomer of LNA) with an aL-ribo configuration, 2′-amino-LNA with a 2′-amino functionalization, and 2′-amino-a-LNA with a 2′-amino functionalization), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA), or hybrids or combinations thereof.

[0059] Thus, disclosed herein are polynucleotides, particularly polypeptide sequences, that encode peptides or polypeptides that contain substitutions, insertions and / or additions, deletions, and covalent modifications relative to a reference sequence. For example, sequence tags or amino acids, such as one or more lysines, can be added (e.g., at the N-terminus or C-terminus) to the peptide sequences described herein. Sequence tags can be used for purifying or localizing the peptide. Lysines can be used to increase the solubility of the peptide or to allow biotinylation. Alternatively, amino acid residues located at the carboxy- and amino-terminal regions of the amino acid sequence of a peptide or protein can be optionally deleted to provide a truncated sequence. Alternatively, specific amino acids (e.g., C-terminal or N-terminal residues) can be deleted depending on the use of the sequence, such as expression of the sequence as part of a larger sequence that is soluble or linked to a solid support.

[0060] Once any of the above features have been identified or defined as desired components of the polypeptides encoded by the polynucleotides described herein, any of the manipulations and / or modifications of these features may be performed by moving, swapping, inverting, deleting, randomizing, or duplicating. It is further understood that the manipulation of features may produce the same results as the modifications to the molecules described herein. For example, manipulations involving the deletion of domains will result in a change in the length of the molecule, as will modifying the nucleic acid to encode a molecule that is shorter than the length of the entire molecule.

[0061] III. Pharmaceutical Compositions and Delivery The fusion polypeptides described herein can be used as therapeutic agents. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one pharma- ceutically acceptable carrier and the fusion polypeptide.

[0062] In some embodiments, the composition is administered to a human, human patient, or subject. Although the description of pharmaceutical compositions provided herein is directed primarily to pharmaceutical compositions suitable for administration to humans, those skilled in the art will understand that such compositions are generally suitable for administration to other animals, such as non-human animals, such as mammals other than humans. Modifications of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals are well understood, and veterinary pharmacologists of ordinary skill can design and / or perform such modifications with no more than routine experimentation. Subjects to which the pharmaceutical composition may be administered include, but are not limited to, humans and / or other primates; mammals (including commercially relevant mammals such as dogs, cows, pigs, horses, sheep, cats, mice, and / or rats); and / or birds (including commercially relevant birds such as poultry, chickens, ducks, geese, and / or turkeys). As a non-limiting example, the compositions of the present disclosure may be administered to dogs to treat ARVC.

[0063] Provided herein are fusion polypeptides and pharmaceutical compositions thereof that can be used in combination with one or more pharma- ceutically acceptable excipients. In some embodiments, pharma- ceutically acceptable excipients include, but are not limited to, any solvent, dispersion medium, diluent, or other liquid vehicle, dispersing or suspending aid, surfactant, isotonicity agent, thickening or emulsifying agent, preservative, solid binder, lubricant, flavoring agent, stabilizer, antioxidant, osmolality adjusting agent, pH adjusting agent, etc., as may be appropriate for the particular dosage form desired. Various excipients for formulating pharmaceutical compositions and techniques for preparing compositions are known in the art (see Remington: The Science and Practice of Pharmacy, 21st Ed., A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporated herein by reference in its entirety)). The use of any conventional excipient medium is contemplated within the scope of this disclosure, except insofar as such excipient medium is incompatible with the substances of the pharmaceutical composition or their derivatives, e.g., by producing undesirable biological effects or by interacting in a deleterious manner with other components, such use is considered to be within the scope of this disclosure.

[0064] In some embodiments, a pharma- ceutically acceptable excipient may be at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient may be approved by the U.S. Food and Drug Administration. In some embodiments, the excipient may be of pharmaceutical grade. In some embodiments, the excipient may meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.

[0065] Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surfactants and / or emulsifying agents, disintegrating agents, binders, preservatives, buffers, lubricants, and / or oils. Such excipients may be optionally included in the pharmaceutical composition. The composition may also include excipients such as cocoa butter and suppository waxes, colorants, coating agents, sweeteners, flavoring agents, and / or perfuming agents.

[0066] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate, lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and the like, and / or combinations thereof.

[0067] Exemplary granulating and / or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinylpyrrolidone (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethylcellulose, cross-linked sodium carboxymethylcellulose (croscarmellose), methylcellulose, pregelatinized starch (Starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (VEEGUM®), sodium lauryl sulfate, quaternary ammonium compounds, and the like, and / or combinations thereof.

[0068] Exemplary surfactants and / or emulsifiers include, but are not limited to, natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chon-drux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, lanolin, cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and VEEGUM® (magnesium aluminum silicate), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate (TWEEN® 20), polyoxyethylene sorbitan (TWEEN® 60), polyoxyethylene sorbitan monooleate (TWEEN® 80), sorbitan monopalmitate (SPAN® 40), sorbitan monostearate (SPAN® 60), sorbitan tristearate (SPAN® 65), glyceryl monooleate, sorbitan monooleate (SPAN® 66), sorbitan oleate (SPAN® 67), sorbitan oleate (SPAN® 68), sorbitan oleate (SPAN® 69), sorbitan oleate (SPAN® 70), sorbitan oleate (SPAN® 71), sorbitan oleate (SPAN® 72), sorbitan oleate (SPAN® 73), sorbitan oleate (SPAN® 74), sorbitan oleate (SPAN® 75), sorbitan oleate (SPAN® 76), sorbitan oleate (SPAN® 77), sorbitan oleate (SPAN® 78), sorbitan oleate (SPAN® 79 ... 80), polyoxyethylene esters (e.g., polyoxyethylene monostearate (MYRJ® 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL®), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., CREMOPHOR®), polyoxyethylene ethers (e.g., polyoxyethylene lauryl ether (BRIJ® 30), poly(vinylpyrrolidone), diethylene glycol monolaurate,Triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONIC® F68, POLOXAMER® 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and / or combinations thereof.

[0069] Exemplary binders include, but are not limited to, starches (e.g., corn starch and starch paste), gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); amino acids (e.g., glycine); natural and synthetic gums (e.g., acacia, sodium alginate, Irish moss extract, panwar gum, ghatti gum, mucilage of isapol husk, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (VEEGUM®), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohols, and the like; and combinations thereof.

[0070] Exemplary preservatives include, but are not limited to, antioxidants, chelating agents, antibacterial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and / or other preservatives. Oxidation is a potential degradation pathway for mRNA, especially liquid mRNA formulations. To prevent oxidation, antioxidants can be added to the formulation. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, EDTA, m-cresol, methionine, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, thioglycerol, and / or sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, edetate disodium, edetate dipotassium, edetate, fumaric acid, malic acid, phosphoric acid, edetate sodium, tartaric acid, and / or edetate trisodium. Exemplary antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and / or thimerosal. Exemplary antifungal preservatives include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and / or sorbic acid. Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoates, and / or phenylethyl alcohol.Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and / or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANTPLUS®, PHENONIP®, methylparaben, GERMALL® 115, GERMABEN®, NEOLONE®, KATHON®, and / or EUXYL®.

[0071] In some embodiments, the pH of the pharmaceutical solution is maintained between pH 5 and pH 8 to improve stability. Exemplary buffers for controlling pH include, but are not limited to, sodium phosphate, sodium citrate, sodium succinate, histidine (or histidine-HCl), sodium carbonate, and / or sodium malate. In another embodiment, the exemplary buffers listed above can be used with additional monovalent counterions, including, but not limited to, potassium. Divalent cations may also be used as buffer counterions, although they are not preferred as they form complexes and / or degrade mRNA.

[0072] Exemplary buffering agents include, but are not limited to, citrate buffer, acetate buffer, phosphate buffer, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, hydroxide calcium phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and the like, and / or mixtures thereof.

[0073] Exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and the like, and combinations thereof.

[0074] Exemplary oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, blackcurrant seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, Oils include lemon, litsea cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, camellia, vetiver, walnut, and wheat germ. Exemplary oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and / or combinations thereof.

[0075] Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and / or perfuming agents can be present in the composition, according to the judgment of the formulator. Exemplary additives include the addition of physiologically biocompatible buffers (e.g., trimethylamine hydrochloride), chelating agents (e.g., DTPA or DTPA-bisamide, etc.) or calcium chelate complexes (e.g., calcium DTPA, CaNaDTPA-bisamide, etc.), or, optionally, calcium or sodium salts (e.g., calcium chloride, calcium ascorbate, calcium gluconate, or calcium lactate). Additionally, antioxidants and suspending agents may be used.

[0076] In some embodiments, compositions of the present disclosure may be administered by any route that produces a therapeutically effective result, including, but not limited to, enteral (into the gut), gastrointestinal, epidural (into the dura), oral (through the mouth), transdermal, peridural, intracerebral (into the brain), intraventricular (into the ventricles of the brain), epicutaneous (applied to the skin), intradermal (into the skin itself), subcutaneous (under the skin), intranasal (through the nose), intravenous (into a vein), intravenous bolus, intravenous drip, intraarterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), intraosseous injection (into the bone marrow), intrathecal (into the spinal canal), intraperitoneal (injected into the peritoneum or injection), intravesical instillation, intravitreal, (from the eye), intracavernous injection (into a pathological cavity), intracavitary (into the base of the penis), intravaginal administration, intrauterine, extra-amniotic administration, transdermal (diffusion through intact skin for systemic distribution), transmucosal (diffusion through mucous membranes), intravaginal, inhalation (breathed through the nose), sublingual, sublabial, enema, eye drops (on the conjunctiva), ear drops, auricular (in or through the ear), buccal (towards the cheek), conjunctival, dermal, dental (to one or more teeth), electroosmosis, intracervical, intranasal, intratracheal, extracorporeal acorporeal), hemodialysis, infiltrating, interstitial, intraperitoneal, intra-amniotic, intra-articular, intra-bile duct, intra-bronchial, intra-synovial (intrabursal), intrachondral (in cartilage), intracaudal (in cauda equina), intracisternal (in cisterna magna, cerebellum oblongata), intracorneal (in cornea), intracoronary (in coronary artery), intracavernosal (in the expandable space of the corpus cavernosum of the penis), intradiscal (in intervertebral disc), intraductal (in glandular duct), intraduodenal (in duodenum), intradural (in or under dura), intraepidermal (to the epidermis), intraesophageal (to the esophagus), intragastric (in the stomach), intragingival ( in the gingiva), intraileal (in the distal part of the small intestine), intralesional (in a local lesion or introduced directly into a local lesion), intraluminal (in the lumen of a tube), intralymphatic (in the lymph), intramedullary (in the medullary cavity of a bone), intrameningeal (in the meninges), intraocular (in the eye), intraovarian (in the ovary), intrapericardial (in the pericardium), intrapleural (in the pleura), intraprostatic (in the prostate), intrapulmonary (in the lungs or their bronchi), intrasinus (in the nose or periorbital sinuses), intraspinal (in the spinal column), intrasynovial (in the synovial cavity of a joint), intratendinous (in tendons), intratesticular (in the testes), intrathecal (in the cerebrospinal fluid at any level of the neuraxis).intrathoracic (inside the chest cavity), intraductal (inside the tubules of an organ), intratumoral (inside a tumor), intratympanic (inside the middle ear), intravascular (into one or more blood vessels), intravenous (into a vein), iontophoresis (using an electric current to move ions of soluble salts into body tissues), irrigation (to bathe or flush an open wound or body cavity), laryngeal (directly into the larynx), nasogastric (through the nose into the stomach), occlusive dressing techniques, ophthalmic (into the external eye), oropharyngeal (directly into the mouth and pharynx), parenteral, percutaneous, periarticular, peridural, and neurologic. These include percutaneous, periodontal, rectal, respiratory (into the airways by inhalation through the mouth or nose for local or systemic effect), retrobulbar (behind the pons or behind the eye), intramyocardial (into the myocardium), soft tissue, subarachnoid, subconjunctival, submucosal, transplacental (through or across the placenta), transtracheal (through the wall of the trachea), transtympanic (across or through the tympanic cavity), ureteral (to the ureter), urethral (to the urethra), vaginal, cavity, sacral anesthesia, diagnostic, nerve block, bile perfusion, cardiac perfusion, photopheresis, or spinal. In certain embodiments, the compositions may be administered in a manner that allows them to cross the blood-brain barrier, blood vessel barrier, or other epithelial barrier.

[0077] A therapeutically effective amount may be readily determined by one of ordinary skill in the art, and will depend on the severity and course of the disease, the patient's health status and response to treatment, and the judgment of the treating physician. IV.How to use Provided herein are methods of using the DSG2 fusion polypeptide compositions of the present disclosure. In some embodiments, the DSG2 fusion polypeptides of the present disclosure can be used to treat one or more diseases or conditions described herein in a subject. Such methods can include contacting a subject with a DSG2 fusion polypeptide. In some embodiments, contacting a subject can include administering a DSG2 fusion polypeptide to the subject. In some embodiments, contacting a subject can include treating the subject with a DSG2 fusion polypeptide of the present disclosure. In one embodiment, the compositions of the present disclosure can be used to treat diseases associated with DSG2 autoantibodies. In one embodiment, the compositions of the present disclosure reduce cardiotoxicity associated with DSG2 antibodies.

[0078] In some embodiments, any disease to be treated that is related to myocardial inflammation can be treated with the DSG2 fusion polypeptide described herein.Non-limiting examples of such indications include arrhythmogenic right ventricular cardiomyopathy (ARVC), sarcoidosis, dilated cardiomyopathy, post-infectious cardiomyopathy, cardiac function reduction, reduced ejection fraction, heart failure, arrhythmia and myocarditis.

[0079] The effectiveness of treating or ameliorating a disease can be assessed, for example, by measuring disease progression, disease remission, severity of symptoms, pain relief, quality of life, amount of drug required to maintain therapeutic effect, disease markers, or other measurable parameters appropriate for a given disease to be treated or prevented. It is within the ability of one of skill in the art to monitor the effectiveness of treatment or prevention by measuring any one of such parameters, or any combination of parameters. In the context of administration of a fusion polypeptide or pharmaceutical composition thereof, "effective against" a disease or disorder refers to a beneficial effect, such as amelioration of symptoms, cure, reduction in disease burden, extension of life, improvement in quality of life, reduction in the need for blood transfusions, or other effect generally recognized as favorable by physicians familiar with the treatment of that particular type of disease or disorder, when administered in a clinically relevant manner, in at least some patients.

[0080] Therapeutic or prophylactic efficacy is evident when there is a substantial (often statistically significant) improvement in one or more parameters of the disease state, or when there is no worsening or onset of the expected symptoms. As an example, a favorable change of at least 10%, preferably at least 20%, 30%, 40%, 50% or more in a measurable parameter of the disease may be indicative of an effective treatment. The efficacy of a given compound or composition may also be determined using an experimental animal model of a given disease, as known in the art. When an experimental animal model is used, the efficacy of the treatment is demonstrated when a statistically significant change in a marker or symptom is observed.

[0081] COVID-19 The DSG2 fusion polypeptides described herein or compositions comprising the fusion polypeptides can be administered to treat COVID-19 or the long-term effects of COVID-19.

[0082] In some embodiments, the compositions of the present disclosure may be useful for treating individuals infected with COVID-19 and / or SARS-CoV-2. Infected individuals may be symptomatic, pre-symptomatic, and asymptomatic. According to the World Health Organization (WHO), COVID-19 infection may result from symptomatic, pre-symptomatic, and asymptomatic people infected with SARS-CoV-2. Symptomatic infection may refer to infection that occurs before a person experiences symptoms. Pre-symptomatic infection may refer to infection that occurs before COVID-19 symptoms appear.

[0083] COVID-19 may be accompanied by one or more symptoms including, but not limited to, fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, stuffy or runny nose, nausea or vomiting, diarrhea, trouble breathing, and persistent pain or pressure in the chest.

[0084] DSG2 fusion polypeptides may be used to treat one or more stages of COVID-19 disease. Typically, adults with SARS-CoV-2 infection are classified into the following severity categories: 1) SARS-CoV-2 infection; 2) SARS-CoV-2 infection; 3) SARS-CoV-2 infection; 4) SARS-CoV-2 infection; 5) SARS-CoV-2 infection; 6) SARS-CoV-2 infection; 7) SARS-CoV-2 infection; 8) SARS-CoV-2 infection; 9) SARS-CoV-2 infection; 10) SARS-CoV-2 infection; 11) SARS-CoV-2 infection; 12) SARS-CoV-2 infection; 13) SARS-CoV-2 infection; 14) SARS-CoV-2 infection; 15) SARS-CoV-2 infection; 16) SARS-CoV-2 infection; 17) SARS-CoV-2 infection; 18) SARS-CoV-2 infection; 19) SARS-CoV-2 infection; 20) SARS-CoV-2 infection; 21) SARS-CoV-2 infection; 22) SARS-CoV-2 infection; 23) SARS-CoV-2 infection; 24) SARS-CoV-2 infection; 25) SARS-CoV-2 infection; 26) SARS-CoV-2 infection; 27) SARS-CoV-2 infection; 28) SARS-CoV-2 infection; 29) SARS-CoV-2 infection; 29) SARS-CoV-2 infection; 30) SARS-CoV-2 infection; 31) SARS-CoV-2 infection; 32) SARS-CoV-2 infection; 33) SARS-CoV-2 infection; 34) SARS-CoV-2 infection; 35) SARS-CoV-2 infection; 36) SARS-CoV In some embodiments, compositions of the present disclosure may be used to treat mild disease, including individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, fatigue, headache, myalgia, nausea, vomiting, diarrhea, loss of taste or smell), but no shortness of breath, difficulty breathing, or chest imaging abnormalities. In some embodiments, compositions of the present disclosure may be used to treat moderate disease, including individuals who show evidence of lower respiratory tract disease during clinical evaluation or imaging and have an oxygen saturation (SpO2) of ≥ 94% on room air at sea level. In some embodiments, compositions of the present disclosure may be used to treat severe disease, including individuals who have an SpO2 < 94% on room air at sea level, a ratio of arterial blood oxygen pressure to inspired oxygen pressure (PaO2 / FiO2) < 300 mmHg, a respiratory rate > 30 breaths / min, or pulmonary infiltrates > 50%. In some embodiments, compositions of the present disclosure may be used to treat critical illnesses, including individuals with respiratory failure, pneumonia, acute respiratory distress syndrome (ARDS), sepsis, septic shock, multiple organ failure, and / or multiple organ dysfunction, including acute kidney injury and cardiac injury.

[0085] Also provided herein are methods of preventing one or more conditions associated with COVID-19. In one embodiment, since there is an incubation period between exposure to the virus and the onset of symptoms, the compositions of the present disclosure can be provided to a subject prior to the onset of symptoms but after exposure to the virus. The incubation period for the novel coronavirus SARS-CoV-2 is typically 2-14 days, with an average of 5 days (Lombardi et al., J. Hosp. Infect. 2020doi:10.1016 / j.jhin.2020.03.003; the contents of which are incorporated herein by reference in their entirety).

[0086] The compositions of the present disclosure may also be administered in combination with one or more therapeutic agents recommended for use in the treatment of COVID-19. In some embodiments, the DSG2 fusion polypeptides described herein may be used in combination with one or more therapeutic agents, such as, but not limited to, remdesivir, chloroquine, hydroxychloroquine, loop diuretics, azithromycin, lopinavir, ritonavir, ivermectin, interleukin inhibitors, interferons, kinase inhibitors, glucocorticosteroids, and / or SARS CoV-2 monoclonal antibodies (e.g., bamlanivimab, casirivimab, imdevimab).

[0087] Post-COVID-19 syndrome In some embodiments, the compositions of the present disclosure may be used to treat post-COVID-19 syndrome. There are increasing reports of patients experiencing persistent symptoms after recovery from acute COVID-19, referred to herein as "post-COVID-19 syndrome," and individuals suffering from these symptoms are commonly referred to as "long haulers." In some embodiments, a patient may be considered to be suffering from post-COVID-19 syndrome if they have one or more symptoms for up to 1 month, up to 2 months, up to 3 months, up to 4 months, up to 5 months, up to 6 months, up to 7 months, up to 8 months, up to 9 months, up to 10 months, up to 11 months, up to 1 year, or more following SARS CoV-2 infection. In some embodiments, a subject may not exhibit symptoms following SARS CoV-2 infection. In some embodiments, a subject may not have a known COVID-19 or SARS CoV2 infection, but may have serum anti-DSG2 antibodies.

[0088] The compositions of the present disclosure may be used to treat one or more symptoms related to the cardiovascular system in post-COVID-19 syndrome (i.e., post-COVID-19 cardiac syndrome). In one study involving 100 patients who had recently recovered from COVID-19, cardiac magnetic resonance imaging revealed cardiac lesions in 78 (78%) patients and ongoing myocardial inflammation in 60 (60%) patients, which was independent of pre-existing symptoms, severity, and overall course of acute disease, as well as time since initial diagnosis (Puntmann et al. JAMA Cardiol. 2020;5(11):1265-1273). In a smaller study, 15% of athletes had evidence of myocarditis after recovery from acute COVID-19. In one embodiment, DSG2 fusion polypeptides may be used to treat myocarditis in subjects with post-COVID-19 syndrome.

[0089] In some embodiments, the compositions described herein may be used to treat post-COVID-19 syndrome that is not associated with any cardiac manifestations. In some embodiments, the compositions of the present disclosure may be used to treat subjects exhibiting symptoms of COVID-19 for up to weeks, months, and / or years after an initial diagnosis of COVID-19. In some embodiments, post-COVID-19 syndrome patients may exhibit symptoms for and / or after 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, or more after an initial diagnosis of COVID-19. A diagnosis of COVID-19 may be established using methods known in the art (e.g., reverse transcription polymerase chain reaction and / or antibody testing). In some embodiments, subjects suffering from post-COVID-19 syndrome may be treated with the compositions of the present disclosure for up to 1 week, up to 1 month, and / or up to 1 year.

[0090] In some embodiments, compositions of the present disclosure may be used to treat COVID-19 patients who have or develop reduced cardiac function, most notably reduced ejection fraction, with or without overt symptoms of heart failure. In some embodiments, compositions of the present disclosure may be used to treat arrhythmias.

[0091] The compositions of the present disclosure can improve one or more symptoms associated with post-COVID-19 syndrome. In some embodiments, the symptoms of post-COVID-19 syndrome can be the same as acute COVID-19. In some embodiments, the symptoms associated with post-COVID-19 syndrome can be shortness of breath, fatigue, edema, orthopnea, limited movement, impaired cognitive ability, palpitations, dizziness, fainting, lightheadedness, heart failure, and / or arrhythmia.

[0092] In some embodiments, compositions of the present disclosure may be used to treat post-COVID-19 syndrome, with symptoms that overlap with post-intensive care syndrome, which has also been reported in patients without COVID-19.

[0093] In some embodiments, compositions of the present disclosure may be used to treat subjects with post-COVID-19 syndrome who may have one or more long-term complications related to the cardiovascular system (e.g., inflammation of the heart muscle), respiratory system (pulmonary function abnormalities), renal system (acute kidney injury), skin disorders (rashes, hair loss), neurological disorders (smell and taste problems, sleep disorders, poor concentration, memory impairment), and / or psychiatric disorders (depression, anxiety, mood changes).

[0094] In some embodiments, the compositions of the present disclosure may be used to treat a subject with post-COVID-19 syndrome who may have one, two or more associated comorbidities. Non-limiting examples of comorbidities include, but are not limited to, hypertension, thyroid disease, immune disorders, COPD (chronic obstructive pulmonary disease), high blood pressure, obesity, mental health conditions, and diabetes.

[0095] Autoimmunity Associated with COVID-19 From a pathogenesis perspective, viral infections such as COVID-19 generally trigger vigorous immune responses with a cascade of events involving both the innate and adaptive immune systems, essential for viral clearance. Direct and indirect myocardial damage can also be caused by COVID-19 infection, exposing cardiac proteins to the activated immune system. Immunological changes are also observed in patients with COVID-19 infection. These range from maladaptive immune responses and aberrant cytokine / chemokine production to hyperactivation of T cells and increased numbers of activated monocytes, macrophages, and neutrophils.

[0096] Autoantibodies known to occur in many autoimmune diseases were detected in COVID-19 patients. COVID-19 infection may break immune tolerance and trigger autoimmune responses, and therefore may also induce clinical autoimmunity. Autoantibodies detected in COVID-19 patients included antinuclear antibodies (ANA), antiphospholipids (APL), lupus anticoagulant, cold agglutinin, anti-Ro / Sjogren's syndrome A (SSA) antibodies, anti-Caspr2 antibodies, anti-GD1b antibodies, anti-myelin oligodendrocyte glycoprotein (MOG) antibodies, and erythrocyte-binding antibodies (Liu, Y., et al. Curr. Opin. Rheumatol. 2021;33:155-162; the contents of each of which are incorporated herein by reference in their entirety). In some embodiments, the compositions of the present disclosure may be used to block autoantibodies generated during COVID-19 or SARS CoV2 infection.

[0097] In one study, three protein arrays were assembled to measure the response of IgG autoantibodies associated with collagen diseases, anti-cytokine antibodies, and anti-viral antibodies in the serum of 147 hospitalized COVID-19 patients. Autoantibodies were identified in approximately 50% of patients, compared with less than 15% in healthy controls. Autoantibodies were found to target autoantigens associated with rare diseases such as myositis, systemic sclerosis, and overlap syndromes. However, a subset of autoantibodies targeting traditional autoantigens or cytokines emerged de novo after COVID-19 infection (Chang, SE, et al. Nature Communications 2021;12:5417; the contents of each are incorporated herein by reference in their entirety). In some embodiments, the compositions of the present disclosure may be used to block autoantibodies that arise after COVID-19 infection.

[0098] In severe and critical cases, immunomodulatory drugs and biologics targeting proinflammatory cytokines have been applied to suppress the strong immune response in COVID-19. Corticosteroids, JAK inhibitors, IL-1 blockers, and IL-6 receptor antagonists have been used to treat COVID-19 patients. In some embodiments, the compositions of the present disclosure may be used in combination with immunomodulatory drugs and biologics targeting proinflammatory cytokines. In some embodiments, the compositions of the present disclosure may be used in combination with corticosteroids, JAK inhibitors, IL-1 blockers, and IL-6 receptor antagonists.

[0099] Thromboembolic events have been reported following ChAdOx1 nCov-19 (AstraZeneca) vaccination and potentially Ad26.COV2.S (Johnson & Johnson) vaccination. Although rare, thrombosis has been observed to occur at unusual sites, such as cerebral and splanchnic veins. This has been suggested to be an immune-mediated response based on observed thrombocytopenia and elevated antibodies against platelet factor 4 polyanion complexes (Lee, CCE, et al. Diseases 2021;9:47; the contents of each of which are incorporated herein by reference in their entirety).

[0100] In one study, a high-throughput autoantibody discovery method known as Rapid Extracellular Antigen Profiling (REAP) was performed to screen a cohort of 194 COVID-19-infected individuals, consisting of 172 COVID-19 patients and 22 healthcare workers with mild or asymptomatic infection, for autoantibodies against 2,770 extracellular and secreted proteins (members of the exoproteome). Screening of patient samples was followed by identification and validation of immunological and physiological functions of numerous protein targets across a wide range of tissues. These autoantibodies have robust functional activity and may directly correlate in vivo with various virological, immunological, and clinical parameters in COVID-19 patient samples. Analysis suggested that some of these autoantibodies likely predate infection, while others were induced after infection. Furthermore, mouse surrogates of these autoantibodies increased disease severity in a mouse model of COVID-19 infection. These results provide evidence that autoantibodies can alter the course of COVID-19 by disrupting immune responses to SARS-CoV2 and tissue homeostasis (Wang, EY, et al. Nature 2021; 595:283; the contents of each of which are incorporated herein by reference in their entirety). In some embodiments, the compositions of the present disclosure can be used to block autoantibodies that were present prior to COVID-19 infection. In some embodiments, the compositions of the present disclosure can be used to block autoantibodies that may be induced following COVID-19 infection.

[0101] Cardiomyopathy In some embodiments, the compositions of the present disclosure can be used to treat cardiomyopathy. Cardiomyopathy refers to the progressive impairment of the structure and function of the muscular wall of the heart chamber. The compositions of the present disclosure can be used to treat one or more types of cardiomyopathy, including, but not limited to, dilated cardiomyopathy, hypertrophic cardiomyopathy, and / or restrictive cardiomyopathy. In one embodiment, cardiomyopathy patients may show serum DSG2 autoantibodies in serum.

[0102] In one embodiment, the composition of the present disclosure can be used to treat arrhythmogenic right ventricular cardiomyopathy (ARVC). Arrhythmogenic right ventricular cardiomyopathy / dysplasia (ARVC / ARVD) is a myocardial disease associated with ventricular arrhythmias, heart failure, and sudden death. ARVC is a degenerative heart disease characterized by progressive loss of ventricular function and arrhythmias. In addition to genetic mutations in structural and signaling proteins of cardiomyocyte desmosomes, the patient's immune system is also known to be involved in the pathology of ARVC disease. Mutations in the DSG2 protein have been associated with ARVC, and autoantibodies targeting DSG2 have been identified in patients with this disease. Approximately 50% of ARVC patients do not have known desmosomal mutations. Nevertheless, these patients express DSG2 antibodies. In some embodiments, DSG2 fusion proteins can be used to treat ARVC patients with one or more mutations in the DSG2 protein. In some aspects, DSG2 fusion proteins can be used to treat ARVC patients with no known mutations in the DSG2 protein. In some embodiments, the DSG2 fusion polypeptides of the present disclosure may target DSG2 autoantibodies associated with ARVC.

[0103] Cardiomyopathy may involve inflammation, referred to herein as myocarditis. In some embodiments, myocarditis may be caused by a virus, bacteria, parasite, and / or fungus. In some embodiments, the compositions of the present disclosure may be used to treat and / or prevent myocarditis associated with a virus. Non-limiting examples of viruses associated with myocarditis include adenoviruses that cause the common cold, COVID-19; hepatitis B and C; parvoviruses (usually causing a mild rash in children (fifth disease)); and / or herpes simplex viruses, echoviruses that cause gastrointestinal infections, Epstein-Barr virus that causes mononucleosis, rubella, cytomegalovirus, and HIV.

[0104] Cardiovascular complications are frequent in association with COVID-19, even months after infection. These cardiovascular complications include myocardial injury and myocarditis, acute coronary syndromes, heart failure, arrhythmias, and thromboembolic events. Additionally, cardiac symptoms, palpitations, chest pain, and dyspnea are observed in patients weeks to months after initial infection. (Lee, CCE, et al. Diseases 2021; 9:47; the contents of each of which are incorporated herein by reference in their entirety). In some embodiments, the compositions of the present disclosure may be used to treat cardiovascular complications, such as myocardial injury and myocarditis, acute coronary syndromes, heart failure, arrhythmias, and thromboembolic events.

[0105] In some embodiments, the compositions of the present disclosure may be used to treat and / or prevent myocarditis caused by bacteria. Non-limiting examples of bacteria associated with myocarditis include Staphylococcus, Streptococcus, and / or Borrelia. In some embodiments, the compositions of the present disclosure may be used to treat and / or prevent myocarditis caused by parasites. Non-limiting examples of parasites associated with myocarditis include Trypanosoma cruzi and Toxoplasma, including those that are transmitted by insects and can cause a condition called Chagas disease. In some embodiments, the compositions of the present disclosure may be used to treat and / or prevent myocarditis caused by fungi. Non-limiting examples of fungi associated with myocarditis include Candida, Aspergillus; and other fungi such as Histoplasma.

[0106] V. Definition Domain: As used herein, the term "domain," when referring to a polypeptide, refers to a motif in a polypeptide having one or more distinguishable structural or functional features or characteristics (e.g., a binding capacity that serves as a site of protein-protein interaction).

[0107] Expression vector: As used herein, the term "expression vector" refers to a vector that contains a nucleic acid sequence that codes for at least a portion of a transcribable gene product. Expression vectors can contain various control sequences, which refer to nucleic acid sequences necessary for the transcription, and possibly translation, of an operably linked coding sequence in a particular host organism. In addition to control sequences that control transcription and translation, vectors and expression vectors can also contain nucleic acid sequences that perform other functions. The term also includes recombinant plasmids or viruses that contain a polynucleotide that is delivered to a host cell in vitro or in vivo. In some embodiments, the host cell is a transient or stable cell line. In some embodiments, it is selected from the group consisting of CHO, HEK293, and NSO.

[0108] Feature: A "feature" when referring to a polypeptide is defined as a distinct amino acid sequence-based component of a molecule. Features of the polypeptides encoded by the polynucleotides described herein include local conformational shapes, folds, loops, half-loops, domains, half-domains, sites, termini, or any combination thereof.

[0109] Fusion protein: As used herein, the term "fusion protein" or chimeric protein refers to a protein or polypeptide that contains two or more sequences of non-naturally occurring amino acids or active fragments thereof in the same polypeptide. In some embodiments, two or more separate polypeptides are operably linked, e.g., chemically linked or fused together by peptide bonds. Recombinant fusion polypeptides are artificially created by recombinant DNA technology.

[0110] Half domain: As used herein when referring to a polypeptide, the term "half domain" refers to a portion of an identified domain that has at least half the number of amino acid residues as the domain from which it is derived. It is understood that a domain does not always contain an even number of amino acid residues. Thus, if a domain contains or is identified to contain an odd number of amino acids, a half domain of the odd numbered domain constitutes the integer portion or the next integer portion of the domain (number of amino acids in the domain / 2±0.5 amino acids). For example, a domain identified as a 7 amino acid domain may generate half domains of 3 or 4 amino acids (7 / 2=3.5+1-0.5 is 3 or 4). It is also understood that subdomains may be identified within a domain or half domain, and these subdomains do not possess all of the structural or functional properties identified in the domain or half domain from which they are derived. It is also understood that the amino acids comprising any of the domain types herein need not be contiguous along the backbone of the polypeptide (i.e., non-adjacent amino acids may be structurally folded to generate a domain, half domain, or subdomain).

[0111] Immune response: As used herein, the term "immune response" refers to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic diseases. These conditions are characterized by the expression of various factors, such as cytokines, chemokines, and other signaling molecules, that can affect cellular and systemic defense systems.

[0112] Linker: As used herein, "linker" refers to a functional group (e.g., a chemical or polypeptide) that covalently links two or more polypeptides. As used herein, a "peptide linker" is two or more amino acids that are used to link two proteins together.

[0113] Modulation: As used herein, the term "modulation" is art-recognized and refers to the upregulation (i.e., activation or stimulation), downregulation (i.e., inhibition or suppression) of a response, or the two, in combination or separately.

[0114] Polynucleotide: The term "polynucleotide" as used herein refers to a sequence of nucleotides linked by phosphodiester bonds. Polynucleotides are presented herein in a 5' to 3' orientation. A polynucleotide can be a deoxyribonucleic acid (DNA) molecule or a ribonucleic acid (RNA) molecule. When the polynucleotide is a DNA molecule, the molecule can be a gene or a cDNA molecule. Nucleotide bases are referred to herein in the single letter code of adenine (A), guanine (G), thymine (T), cytosine (C), inosine (I), and uracil (U). Polynucleotides can be prepared using standard techniques well known to those skilled in the art.

[0115] Polypeptide: In some embodiments, the compositions of the present disclosure are polypeptides or proteins or variants thereof. According to the present disclosure, any amino acid-based molecule (natural or non-natural) may be referred to as a "polypeptide", which term encompasses "peptides", "peptidomimetics", and "proteins". As used herein, "polypeptide" refers to a polymer of amino acid residues (natural or non-natural) most often linked together by peptide bonds. As used herein, the term refers to proteins, polypeptides, and peptides of any size, structure, or function. A "peptidomimetic" or "polypeptide mimetic" is a polypeptide whose molecule contains structural elements not found in naturally occurring polypeptides (i.e., polypeptides composed only of the 20 protein-forming amino acids). In some embodiments, a peptidomimetic can reproduce or mimic the biological action of a natural peptide.

[0116] Polypeptide variant: The term "polypeptide variant" refers to a molecule that differs in amino acid sequence from a native or reference sequence. Amino acid sequence variants may have substitutions, deletions, and / or insertions at specific positions within the amino acid sequence compared to the native or reference sequence. Typically, variants have at least about 50% identity (homology) to the native or reference sequence, and preferably, they are at least about 80%, more preferably at least about 90% identical (homology) to the native or reference sequence.

[0117] Recombinant: As used herein, the term "recombinant" refers to a genetic entity that is distinct from that commonly found in nature. When applied to a polynucleotide or gene, it means that the polynucleotide is the product of various combinations of cloning, restriction and / or ligation steps, and other procedures, that result in the production of constructs that are distinct from polynucleotides found in nature.

[0118] Sample: As used herein, the term "sample" refers to an aliquot or portion taken from a source and / or provided for analysis or processing. In some embodiments, a sample is derived from a biological source, such as a tissue, cell, or component (e.g., bodily fluids, including but not limited to blood, mucus, lymph, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid, and semen). In some embodiments, a sample may be or include a homogenate, lysate, or extract prepared from a whole organism, or a subset of its tissues, cells, or components, or a fraction or portion thereof. These include, but are not limited to, for example, plasma, serum, spinal fluid, lymph, external sections of skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, or organs. In some embodiments, a sample is or includes a medium, such as a nutrient broth or gel, which may contain cellular components, such as proteins. In some embodiments, a "primary" sample is an aliquot of a source. In some embodiments, the primary sample is subjected to one or more processing (eg, separation, purification, etc.) steps to prepare the sample for analysis or other uses.

[0119] Substantially: As used herein, the term "substantially" refers to the qualitative condition indicating the entire or nearly entire extent or degree of a property or characteristic of interest. Those skilled in the biological arts will understand that biological and chemical phenomena are highly unlikely to proceed completely and / or to completion or to absolutely achieve or avoid a result. Thus, the term "substantially" is used herein to express the potential lack of completeness inherent in many biological and chemical phenomena.

[0120] Terminal: When referring to a polypeptide, the term "terminal" as used herein refers to the end of the peptide or polypeptide. Such terminal is not limited to only the first or last site of the peptide or polypeptide, but may include additional amino acids in the terminal region. The polypeptide-based molecules described herein may be characterized as having both an N-terminus (terminated by an amino acid having a free amino group (NH2)) and a C-terminus (terminated by an amino acid having a free carboxyl group (COOH)). The proteins described herein are optionally composed of multiple polypeptide chains (multimers, oligomers) linked by disulfide bonds or non-covalent forces. Such proteins will have multiple N-terminuses and C-terminuses. Alternatively, the termini of the polypeptide may optionally be modified to begin or end with non-polypeptide-based moieties, such as organic complexes.

[0121] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" refers to the amount of agent delivered that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition, to treat, ameliorate the symptoms of, diagnose, prevent, and / or delay the onset of the disease, disorder, and / or condition.

[0122] Treating: As used herein, the term "treating" refers to partially or completely alleviating, ameliorating, improving, relieving, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. Treatment may be administered to subjects who do not show signs of a disease, disorder, and / or condition and / or who show only early signs of a disease, disorder, and / or condition, for the purpose of reducing the risk of developing a pathology associated with the disease, disorder, and / or condition.

[0123] Treatment: As used herein, the terms "treat", "treatment" and the like refer to the alleviation of a pathological process. In the context of this disclosure, as it relates to any of the other conditions listed herein below, the terms "treat", "treatment" and the like refer to the alleviation or amelioration of at least one symptom associated with such condition, or the slowing or reversal of the progression or expected progression of such condition.

[0124] Therapeutic Dose: As used herein, a "therapeutic dose" refers to one or more doses of a therapeutic agent administered in the course of addressing or alleviating a therapeutic indication. A therapeutic dose may be adjusted to maintain a desired concentration or activity level of the therapeutic agent in a bodily fluid or biological system.

[0125] VI. Equivalents and Scope While various embodiments of the present disclosure have been particularly shown and described in this disclosure, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the embodiments disclosed herein and set forth in the appended claims.

[0126] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. The scope of the present disclosure is not limited to the above description, but rather is as set forth in the appended claims.

[0127] In the claims, articles such as "a," "the," and "said" may mean one or more, unless otherwise indicated or clear from the context. A claim or description containing "or" between one or more members of a group is considered to be satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or method, unless otherwise indicated or clear from the context. The present disclosure includes embodiments in which only one member of a group is present in, employed in, or otherwise relevant to a given product or method. The present disclosure includes embodiments in which more than one or all group members are present in, employed in, or otherwise relevant to a given product or method.

[0128] It should also be noted that the term "comprising" is intended to be open, permitting but not requiring the inclusion of additional elements or steps. Thus, when the term "comprising" is used in this application, the terms "consisting of" and "or containing" are also included and disclosed.

[0129] When ranges are given, the boundaries are included. Moreover, unless otherwise indicated or clear from the context and the understanding of one of ordinary skill in the art, it is to be understood that values ​​expressed as ranges may, in various embodiments of the invention, assume any specific value or subrange within the stated range, down to the tenth of the unit of the lower limit of that range, unless the context clearly dictates otherwise.

[0130] Furthermore, it should be understood that any particular embodiment of the present disclosure that falls under the prior art may be expressly excluded from any one or more claims.Such an embodiment is deemed known to those skilled in the art, and therefore may be excluded even if the exclusion is not expressly stated herein.Any particular embodiment of the composition disclosed herein may be excluded from any one or more claims for any reason, whether or not related to the existence of prior art.

[0131] All sources cited herein, including, for example, references, publications, databases, database entries, and art cited herein, are incorporated by reference into this application, even if not explicitly stated in the citation. In the event of a conflict between the sources and the present application, the present application shall control.

[0132] The section and table headings are not intended to be limiting. Working Example Example 1. Method for the synthesis of DSG2 fusion polypeptides The DSG2 fusion polypeptides described herein are produced by recombinant DNA techniques by synthesizing DNA encoding the desired polypeptide. Once the coding sequences for the desired polypeptides have been synthesized or isolated, they are cloned into a suitable vector for expression.

[0133] The expression vector is inserted into a suitable host cell by transformation, transduction, and / or transfection. The sequence of the DSG2 fusion polypeptide can be optimized to provide maximum expression in the host cell. The host cell can be any host cell known in the art for the expression of recombinant proteins. Many mammalian cell lines are known in the art, including immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, HEK293, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., HepG2), Madin-Darby bovine kidney ("MDBK") cells, NOS cells derived from cancer cells such as sarcomas, and others. Bacterial species can also be used as host cells. Non-limiting examples include Escherichia coli, Bacillus subtilis, and Streptococcus. Non-limiting examples of yeast host cells useful in the present disclosure include, among others, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

[0134] Depending on the expression system and host selected, the fusion polypeptides of the present disclosure are produced by growing a host cell expressing an expression vector under conditions in which the protein of interest is expressed, and the protein is then isolated from the host cell and purified.

[0135] Alternatively, fusion polypeptides of the present disclosure can be synthesized by conventional techniques known in the art, for example chemical synthesis, such as solid phase peptide synthesis. Example 2. Anti-DSG2 antibodies in serum samples after COVID-19 It has been hypothesized that viral infections, including COVID-19, contribute to autoimmune responses, for example, by exposing previously hidden cryptic epitopes on damaged cells to the activated immune system (Ehrenfeld M, et al., Autoimmunity Reviews 2020;102597; the contents of which are incorporated herein by reference in their entirety). Given the high incidence of cardiac disease seen in COVID-19 infections, it was hypothesized that anti-DSG2 autoantibodies would result.

[0136] Three hundred convalescent serum samples were collected from a group of post-COV1D-19 infection patients from East Asian population from October 2020 to February 2021. The mean age of the study population was 37 years (range 21-65 years). 154 samples were collected 6 months after COVID-19 infection and 146 samples were collected 9 months after COVID infection. 17 samples were obtained from the same patients at 6 and 9 months (symptom status unknown). Serum of the negative control group was obtained from a commercial source of self-reported healthy individuals. Positive control ARVC serum was obtained according to the International Conference on Harmonization (ICH) guidelines. An anti-drug antibody (ADA) format assay was used for the detection of anti-DSG2 antibodies. As shown in Figure 1, the mean signal intensity of anti-DSG2 antibodies in post-COVID-19 samples was significantly higher than that of the healthy control population (19 ± 83.2 in post-COVID-19 samples vs. 2.1 ± 6.8 in healthy control population, p-value < 0.001). Notably, 29.3% of post-COVID-19 samples had a signal higher than the 90th percentile of the control population, and 8.7% had a signal higher than the median seen in ARVC patients. The presence of anti-DSG2 antibodies in samples taken 6-9 months after COVID-19 infection suggests that the antibodies are not acute-phase reactants. The results are also shown in Tables 4 and 5.

[0137] [Table 4]

[0138] [Table 5]

[0139] Signal strength between 6-month and 9-month samples was not significantly different from each other (p=0.529), observed when all 6-month and 9-month samples were evaluated asynchronously (N=300, Figure 2A), as well as when 6-month and 9-month samples were analyzed paired by month of collection after COVID-19 infection (N=17, Figure 2B).

[0140] In conclusion, recovered COVID-19 patients showed sustained anti-DSG2 autoantibody levels that were significantly higher compared to healthy control populations and comparable to levels in groups diagnosed with ARVC. Of note, these sera were obtained well after acute COVID-19 infection, suggesting that these antibodies may persist for a long time.

Claims

1. 1. An isolated polypeptide comprising a desmoglein 2 (DSG2) fusion polypeptide, said DSG2 fusion polypeptide comprising: a. the whole or part of the DSG2 protein (SEQ ID NO: 1); and b. Proteins or protein fragments capable of improving the expression and / or stability of said DSG2 protein in vitro or in vivo or used for the purification of said DSG2 fusion polypeptides.

2. An isolated polypeptide comprising:

2. The isolated polypeptide of claim 1 , wherein the DSG2 fusion polypeptide comprises a portion of the DSG2 protein.

3. 3. The isolated polypeptide of claim 2, wherein the portion of the DSG2 protein is all or a portion of the extracellular domain of the DSG2 protein.

4. 4. The isolated polypeptide of claim 3, wherein said portion of a DSG2 protein is the entire extracellular domain of a DSG2 protein.

5. The isolated polypeptide of claim 4, wherein the entire extracellular domain of the DSG2 protein comprises the amino acid sequence of SEQ ID NO:

3.

6. 4. The isolated polypeptide of claim 3, wherein the portion of the DSG2 protein is a portion of the extracellular domain of the DSG2 protein.

7. 7. The isolated polypeptide of claim 6, wherein the portion of the extracellular region of the DSG2 protein comprises at least one domain, and the at least one domain is extracellular cadherin domain 1 (EC1), extracellular cadherin domain 2 (EC2), extracellular cadherin domain 3 (EC3), extracellular cadherin domain 4 (EC4), or extracellular anchoring domain (EA).

8. The isolated polypeptide of claim 7 , wherein the portion of the extracellular region of the DSG2 protein comprises two domains.

9. 9. The isolated polypeptide of claim 8, wherein the portion of the extracellular domain of the DSG2 protein is EC4EA, EC1EC2, EC2EC3, EC3EC4, EC1EA, EC1EC3, EC2EC4, or EC3EA.

10. The isolated polypeptide of claim 7, wherein said portion of the extracellular region of the DSG2 protein comprises three domains.

11. 11. The isolated polypeptide of claim 10, wherein the portion of the extracellular domain of the DSG2 protein is EC1EC3EA, EC1EC4EA, EC1EC3EA, EC3EC4EA, EC1EC2EC3, EC2EC3EC4, or EC2EC4EA.

12. 8. The isolated polypeptide of claim 7, wherein said portion of the extracellular region of the DSG2 protein comprises four domains.

13. 13. The isolated polypeptide of claim 12, wherein the portion of the extracellular domain of the DSG2 protein is EC1EC2EC4EA, EC2EC3EC4EA, EC1EC2EC3EC4EA, EC1EC2EC3EC4, or EC1EC2EC3EA.

14. The isolated polypeptide of claim 1 , wherein the protein fragment comprises a portion of an immunoglobulin protein.

15. 15. The isolated polypeptide of claim 14, wherein the immunoglobulin protein is IgG, IgM, IgA, IgD, or IgE.

16. 16. The isolated polypeptide of claim 15, wherein the immunoglobulin is an IgG.

17. 17. The isolated polypeptide of claim 16, wherein the IgG is IgG1, IgG2, IgG3, and IgG4.

18. 15. The isolated polypeptide of claim 14, wherein the portion of the immunoglobulin protein is an Fc region, a Fab region, a heavy chain variable (VH) domain, a heavy chain constant domain, a light chain variable (VL) domain, or a light chain constant domain.

19. 20. The isolated polypeptide of claim 18, wherein the portion of the immunoglobulin protein is an Fc region.

20. 20. The isolated polypeptide of claim 19, wherein the Fc region is an IgG1 Fc region (SEQ ID NO: 5), an IgG2 Fc region (SEQ ID NO: 7), an IgG3 Fc region (SEQ ID NO: 9), or an IgG4 Fc region (SEQ ID NO: 11).

21. 20. The isolated polypeptide of claim 18, wherein said portion of said immunoglobulin protein is a heavy chain constant domain.

22. 22. The isolated polypeptide of claim 21, wherein the heavy chain constant domain is an IgG1 heavy chain constant domain (SEQ ID NO: 4), an IgG2 heavy chain constant domain (SEQ ID NO: 6), an IgG3 heavy chain constant domain (SEQ ID NO: 8), or an IgG4 heavy chain constant domain (SEQ ID NO: 10).

23. 23. The isolated polypeptide of any one of claims 1 to 22, wherein the DSG2 fusion polypeptide further comprises a linker.

24. 24. The isolated polypeptide of claim 23, wherein the linker is from about 5 amino acids to about 50 amino acids in length.

25. 25. The isolated polypeptide of claim 24, wherein the linker is GGGGS (SEQ ID NO: 12).

26. 25. The isolated polypeptide of claim 24, wherein the linker is EAAAK (SEQ ID NO: 13).

27. A cell expressing the isolated polypeptide of any one of claims 1 to 26.

28. 1. Use of a desmoglein 2 (DSG2) fusion polypeptide in the manufacture of a pharmaceutical composition for treating post-COVID-19 syndrome in a subject, the fusion polypeptide comprising: a. the whole or part of the DSG2 protein (SEQ ID NO: 1); and b. Proteins or protein fragments capable of improving the expression and / or stability of said DSG2 protein in vitro or in vivo or used for the purification of said DSG2 fusion polypeptides. Including, use.

29. 29. The use of claim 28, wherein the subject's serum contains anti-DSG2 antibodies.

30. The use of claim 28, wherein the subject has previously been diagnosed with COVID-19.

31. The use according to any one of claims 28 to 30, wherein the protein or protein fragment is a sequence tag.

32. The use described in any one of claims 28 to 31, wherein the portion of the DSG2 protein includes the entire extracellular domain of the DSG2 protein, which comprises the amino acid sequence of SEQ ID NO:

3.

33. The use described in any one of claims 28 to 31, wherein the portion of the DSG2 protein is a portion of the extracellular domain of the DSG2 protein.

34. The use of claim 33, wherein the portion of the extracellular region of the DSG2 protein comprises at least one domain, the at least one domain being extracellular cadherin domain 1 (EC1), extracellular cadherin domain 2 (EC2), extracellular cadherin domain 3 (EC3), extracellular cadherin domain 4 (EC4), or extracellular anchoring domain (EA).

35. The use according to any one of claims 28 to 30 and 32 to 34, wherein the protein or protein fragment capable of improving the expression and / or stability of the DSG2 protein in vitro or in vivo is a whole or part of an immunoglobulin protein.

36. The use of claim 35, wherein the immunoglobulin is IgG.

37. The use of claim 35 or 36, wherein the portion of the immunoglobulin protein is an Fc region.

38. 1. Use of a desmoglein 2 (DSG2) fusion polypeptide in the manufacture of a pharmaceutical composition for treating COVID-19 in a subject, the fusion polypeptide comprising: a. the whole or part of the DSG2 protein (SEQ ID NO: 1); and b. Proteins or protein fragments capable of improving the expression and / or stability of said DSG2 protein in vitro or in vivo or used for the purification of said DSG2 fusion polypeptides. Including, use.

39. 39. The use of claim 38, wherein the subject's serum contains anti-DSG2 antibodies.

40. The use described in claim 38 or 39, wherein the protein or protein fragment is a sequence tag.

41. The use described in any one of claims 38 to 40, wherein the portion of the DSG2 protein includes the entire extracellular domain of the DSG2 protein comprising the amino acid sequence of SEQ ID NO:

3.

42. The use described in any one of claims 38 to 40, wherein the portion of the DSG2 protein is a portion of the extracellular domain of the DSG2 protein.

43. The use of claim 42, wherein the portion of the extracellular region of the DSG2 protein comprises at least one domain, the at least one domain being extracellular cadherin domain 1 (EC1), extracellular cadherin domain 2 (EC2), extracellular cadherin domain 3 (EC3), extracellular cadherin domain 4 (EC4), or extracellular anchoring domain (EA).

44. The use of any one of claims 38, 39 and 41 to 43, wherein the protein or protein fragment capable of improving expression and / or stability of the DSG2 protein in vitro or in vivo is all or part of an immunoglobulin protein.

45. The use of claim 44, wherein the immunoglobulin is IgG.

46. ​​The use of claim 44 or 45, wherein the portion of the immunoglobulin protein is an Fc region.

47. A Desmoglein 2 (DSG2) fusion polypeptide for use in the treatment of a disease or disorder caused by anti-Desmoglein 2 (DSG2) autoantibodies, said fusion polypeptide comprising an extracellular domain of human DSG2 protein or a portion thereof having at least about 85% sequence identity to amino acid residues 50-609 of SEQ ID NO:1, and a protein or protein fragment capable of improving expression and / or stability of said DSG2 protein in vitro or in vivo or for use in the purification of said DSG2 fusion polypeptide.